natgillin/translations-raw huggingface dataset:
The recommended dosage of Truxima for induction of remission therapy of granulomatosis with polyangiitis and microscopic polyangiitis is 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for 4 weeks (four infusions in total). 
Priporočeno odmerjanje zdravila Truxima za indukcijo remisije pri zdravljenju granulomatoze s poliangiitisom in mikroskopskega poliangiitisa je 375 mg/m2 telesne površine v intravenski infuziji 1-krat na teden 4 tedne (skupaj štiri infuzije).
Package leaflet: Information for the patient Truxima 500 mg concentrate for solution for infusion rituximab This medicine is subject to additional monitoring. 
Navodilo za uporabo Truxima 500 mg koncentrat za raztopino za infundiranje rituksimab Za to zdravilo se izvaja dodatno spremljanje varnosti.
Signs and symptoms suggestive of an infusion-related reaction were reported in more than 50% of patients in clinical trials, and were predominantly seen during the first infusion, usually in the first one to two hours. 
bolnikov v kliničnih preskušanjih; večinoma so jih opazili med prvo infuzijo, po navadi v prvih dveh urah.
Package leaflet: Information for the patient Truxima 100 mg concentrate for solution for infusion rituximab This medicine is subject to additional monitoring. 
Navodilo za uporabo Truxima 100 mg koncentrat za raztopino za infundiranje rituksimab Za to zdravilo se izvaja dodatno spremljanje varnosti.
Severe infusion-related reactions (such as bronchospasm, hypotension) occurred in up to 12% of the cases. 
bronhospazem, hipotenzija), so se pojavile pri do 12% bolnikov.
Patient's 
Bolnikom s
Multiple courses of treatment are associated with a similar ADR profile to that observed following first exposure. 
Večkratno zdravljenje Pri večkratnem zdravljenju je profil neželenih učinkov podoben tistemu, ki so ga opazili ob prvem zdravljenju.
In a randomised trial, patients with rheumatoid arthritis treated with rituximab and methotrexate had comparable response rates to tetanus recall antigen (39% vs. 42%), reduced rates to pneumococcal polysaccharide vaccine (43% vs. 82% to at least 2 pneumococcal antibody serotypes), and KLH neoantigen (47% vs. 93%), when given 6 months after rituximab as compared to patients only receiving methotrexate. 
V randomizirani študiji so imeli bolniki z revmatoidnim artritisom, ki so se zdravili z rituksimabom in metotreksatom, v primerjavi z bolniki, ki so dobivali samo metotreksat, podoben delež odgovorov na cepivo proti tetanusu (recall antigen) (39% v primerjavi z 42%), nižji delež odgovorov na polisaharidno cepivo proti pnevmokoku (43% v primerjavi z 82% na vsaj 2 serotipa) in neoantigen KLH (47% v primerjavi s 93%).
This is because Truxima can affect the way some other medicines work. 
Zdravilo Truxima namreč lahko vpliva na delovanje nekaterih drugih zdravil in obratno - tudi nekatera druga zdravila lahko vplivajo na delovanje zdravila Truxima.
Truxima is used to treat rheumatoid arthritis in people who have already tried some other medicines which have either stopped working, have not worked well enough or have caused side effects. 
Zdravilo Truxima se uporablja za zdravljenje revmatoidnega artritisa pri bolnikih, ki so se že zdravili z drugimi zdravili, vendar so prenehala delovati,
The European Medicines Agency has waived the obligation to submit the results of studies with rituximab in all subsets of the paediatric population with autoimmune arthritis. 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z rituksimabom za vse podskupine pediatrične populacije z avtoimunskim artritisom (za podatke o uporabi pri pediatrični
• pain in the muscles 
bolečina v trebuhu, bolečina v mišicah,
Clinical experience in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis 
Klinične izkušnje pri granulomatozi s poliangiitisom (Wegenerjevi granulomatozi) in mikroskopskem poliangiitisu Indukcija remisije
In patients with non-Hodgkin's lymphoma and CLL, premedication with glucocorticoids should be considered if Truxima is not given in combination with glucocorticoid-containing chemotherapy. 
Če zdravilo Truxima za zdravljenje ne-Hodgkinovega limfoma in kronične limfocitne levkemije ni uporabljeno v kombinaciji s kemoterapijo, ki vključuje glukokortikoid, je treba razmisliti o premedikaciji z glukokortikoidi.
Truxima should be administered as two 500 mg IV infusions separated by two weeks, followed by a 500 mg IV infusion every 6 months thereafter. 
Zdravilo Truxima je treba dati v dveh 500-mg intravenskih infuzijah, med katerima mora biti 2tedenski presledek; temu sledijo 500-mg intravenske infuzije na 6 mesecev.
Corticosteroids will usually be given by injection before the start of Truxima treatment. 
Pred začetkom zdravljenja z zdravilom Truxima boste ponavadi dobili kortikosteriod v injekciji.
Truxima monotherapy is indicated for treatment of patients with stage III-IV follicular lymphoma who are chemo-resistant or are in their second or subsequent relapse after chemotherapy. 
Zdravilo Truxima je indicirano za samostojno zdravljenje bolnikov s III. in IV. stadijem folikularnih limfomov, ki so neodzivni na kemoterapijo ali se je pri njih bolezen po kemoterapiji drugič ali že večkrat ponovila.
Vascular disorders hypertension, orthostatic hypotension, hypotension vasculitis (predominate ly cutaneous), leukocytoclas tic vasculitis 
Žilne bolezni hipertenzija, ortostatska hipotenzija, hipotenzija vaskulitis (pretežno kožni),
Kaplan-Meier estimated progression-free rates at 12 months were 78% in the rituximab maintenance group vs. 57% in the observation group. 
Delež bolnikov brez napredovanja bolezni, ocenjen po Kaplan-Meierju, je bil pri 12 mesecih 78% v skupini, ki je prejemala vzdrževalno zdravljenje z rituksimabom, in 57% v opazovani skupini.
In Trial 1, conducted in patients with inadequate response or intolerance to one or more TNF inhibitor therapies, receiving rituximab in combination with methotrexate demonstrated significantly less radiographic progression than patients originally receiving methotrexate alone at 56 weeks. 
TNF ali jih niso prenašali, in ki so prejemali rituksimab in metotreksat, po 56 tednih na posnetkih značilno manj znakov napredovanja kot pri tistih, ki so prvotno dobivali samo metotreksat.
The chemotherapy should be given after the Truxima infusion. 
Kemoterapijo boste dobili po infuziji zdravila Truxima.
The recommended dose of Truxima used as a maintenance treatment for patients with previously untreated follicular lymphoma who have responded to induction treatment is: 375 mg/m2 body surface area once every 2 months (starting 2 months after the last dose of induction therapy) until disease progression or for a maximum period of two years (12 infusions in total). 
Priporočeni odmerek zdravila Truxima za vzdrževalno zdravljenje bolnikov s predhodno nezdravljenimi folikularnimi limfomi, ki so se odzvali na indukcijsko zdravljenje, je: 375 mg/m2 telesne površine enkrat na 2 meseca (z začetkom 2 meseca po zadnjem odmerku indukcijskega zdravljenja) do napredovanja bolezni ali največ dve leti (skupaj 12 infuzij).
You might get infections more easily during your treatment with Truxima. 
Med zdravljenjem z zdravilom Truxima ste lahko bolj nagnjeni k okužbam.
PATIENT ALERT CARD TEXT FOR NON-ONCOLOGY INDICATIONS Truxima (Rituximab) Alert Card for patients with non-oncology diseases Why have I been given this card? 
BESEDILO OPOZORILNE KARTICE ZA BOLNIKA Z NEONKOLOŠKO INDIKACIJO Opozorilna kartica za bolnike, ki prejemajo zdravilo Truxima (rituksimab) za neonkološke bolezni
• The active ingredient in Truxima is called rituximab. 
• Zdravilna učinkovina zdravila Truxima je rituksimab.
LogRank p 
Limfociti B
Experience from granulomatosis with polyangiitis and microscopic polyangiitis Induction of remission 
Izkušnjeprigranulomatoza s poliangiitisom in mikroskopski poliangiitis Indukcija remisije
This should be followed by oral prednisone 1 mg/kg/day (not to exceed 80 mg/day, and tapered as rapidly as possible based on clinical need) 
1 mg/kg/dan prednizona peroralno (odmerek ne sme preseči 80 mg/dan in ga je treba zmanjšati, kolikor hitro je mogoče glede na klinične potrebe) med po 4-tedenskem indukcijskem zdravljenju z zdravilom Truxima.
d) Granulomatosis with polyangiitis or microscopic polyangiitis 
d) granulomatoze s poliangiitisom ali mikroskopskega poliangiitisa
• What you need to know before having 
• Kaj morate vedeti, preden prejmete zdravilo Truxima
Cases of grade 3 or 4 arrhythmia (including ventricular and supraventricular tachycardia) and angina pectoris during infusion were reported. 
Med infuzijo sta se pojavili tudi aritmija 3. ali 4. stopnje (vključno z ventrikularno in supraventrikularno tahikardijo)
This medicine may make you more likely to get infections. 
Ker prejemate zdravilo Truxima, je večja verjetnost, da dobite okužbo.
Skin and Subcutaneou s tissue disorders pruritus, rash, +alopecia urticaria, sweating, night sweats, +skin disorder severe bullous skin reactions, StevensJohnson syndrome, toxic epidermal necrolysis (Lyell's syndrome)7 
+alopecija urtikarija, znojenje, nočno znojenje, +bolezen kože hude bulozne kožne reakcije, StevensJohnsonov sindrom, toksična epidermalna nekroliza (Lyellov sindrom)7
• allergic reactions that are most likely to occur during an infusion, but can occur up to 24 
alergijske reakcije, ki se najverjetneje pojavijo med infuzijo.
Truxima in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory CLL. 
Zdravilo Truxima je v kombinaciji s kemoterapijo indicirano za zdravljenje bolnikov s kronično limfocitno levkemijo, ki predhodno še niso bili zdravljeni oziroma se na prejšnje zdravljenje niso odzvali ali pa se je bolezen pri njih ponovila.
See the Truxima package leaflet for more information. 
Za več informacij preberite navodilo za uporabo zdravila Truxima.
If you are being treated for rheumatoid arthritis 
c) Če se zdravite zaradi revmatoidnega artritisa
Cardiac disorders angina pectoris, atrial fibrillation, heart failure, myocardial infarction atrial flutter 
Srčne bolezni angina pektoris, atrijska fibrilacija,
If patients did not experience a serious infusion-related reaction with their first or subsequent infusions of a dose of 1000 mg Truxima administered over the standard infusion schedule, a more rapid infusion can be administered for second and subsequent infusions using the same concentration as in previous infusions (4 mg/mL in a 250 mL volume). 
1000 mg zdravila Truxima, ki je potekalo v skladu z originalno shemo dajanja, lahko drugo in nadaljnje infuzije prejmejo hitreje z enako koncentracijo kot v prejšnjih infuzijah (4 mg/ml v 250-ml volumnu).
Initial treatment, in combination with chemotherapy In an open-label randomised trial, a total of 322 previously untreated patients with follicular lymphoma were randomised to receive either CVP chemotherapy (cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2 up to a maximum of 2 mg on day 1, and prednisolone 40 mg/m2/day on days 1-5) every 3 weeks for 8 cycles or rituximab 375 mg/m2 in combination with CVP (R-CVP). 
V odprtem randomiziranem preskušanju so skupaj 332 predhodno še nezdravljenih bolnikov s folikularnimi limfomi randomizirali na prejemanje kemoterapije CVP (750 mg/m2 ciklofosfamida, 1,4 mg/m2 vinkristina do največ 2 mg 1. dan in 40 mg/m2/dan prednizolona od 1. do 5. dneva) na 3 tedne 8 ciklov, ali na 375 mg/m2 rituksimaba v kombinaciji s CVP (R-CVP).
The recommended dosage of Truxima in combination with chemotherapy for previously untreated and relapsed/refractory patients is 375 mg/m2 body surface area administered on day 0 of the first treatment cycle followed by 500 mg/m2 body surface area administered on day 1 of each subsequent cycle for 6 cycles in total. 
Priporočeni odmerek zdravila Truxima v kombinaciji s kemoterapijo pri bolnikih, ki predhodno še niso bili zdravljeni oziroma se na prejšnje zdravljenje niso odzvali ali pa se je bolezen pri njih ponovila, je 375 mg/m2 telesne površine, ki ga damo na dan 0 prvega cikla zdravljenja, v naslednjih ciklih zdravljenja pa dajemo 1. dan 500 mg/m2 telesne površine, skupaj 6 ciklov.
Contraindications for use in rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis and pemphigus vulgaris 
Kontraindikacije za uporabo pri revmatoidnem artritisu, granulomatozi s poliangiitisom,mikroskopskem poliangiitisu in navadnem pemfigusu
If patients did not experience a serious infusion related reaction with their first or subsequent infusions of a dose of 1000 mg Truxima administered over the standard infusion schedule, a more rapid infusion can be administered for second and subsequent infusions using the same concentration as in previous infusions (4 mg/mL in a 250 mL volume). 
1.000 mg zdravila Truxima, ki je potekalo v skladu z originalno shemo dajanja, lahko drugo in nadaljnje infuzije prejmejo hitreje z enako koncentracijo kot v prejšnjih infuzijah (4 mg/ml v 250-ml volumnu).
The recommended dose of Truxima in combination with chemotherapy for induction treatment of previously untreated or relapsed/refractory patients with follicular lymphoma is: 375 mg/m2 body surface area per cycle, for up to 8 cycles. 
Priporočeni odmerek zdravila Truxima v kombinaciji s kemoterapijo za indukcijsko zdravljenje bolnikov s folikularnimi limfomi, ki se predhodno še niso zdravili ali se na prejšnje zdravljenje niso odzvali ali se jim je bolezen ponovila, je: 375 mg/m2 telesne površine na cikel do 8 ciklov.
Truxima is a clear, colourless solution, supplied as a concentrate for solution for infusion in a glass vial. 
Na voljo je v obliki koncentrata za raztopino za infundiranje v stekleni viali.
Truxima is used for the treatment of patients with moderate to severe pemphigus vulgaris. 
Zdravilo Truxima se uporablja za zdravljenje bolnikov z zmernim do hudim navadnim pemfigusom.
Log-rank p value 
Vrednost p v testu log-rang
Premedication consisting of an anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine, should always be given before each administration of Truxima. 
Pred uporabo zdravila Truxima mora bolnik vedno dobiti premedikacijo, ki obsega antipiretik in antihistaminik, npr. paracetamol in difenhidramin.
granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris. 
granulomatozo s poliangiitisom, mikroskopski poliangiitis ali navadni pemfigus.
You must also do this for 12 months after your last treatment with Truxima. 
Učinkovito kontracepcijsko zaščito morate nadaljevati še 12 mesecev po zadnjem odmerku zdravila Truxima.
Rituximab was administered as an intravenous infusion at a first-cycle dose of 375 mg/m2 increased to 500 mg/m2 each cycle for 5 doses in combination with fludarabine and cyclophosphamide in CLL patients. 
Rituksimab so bolnikom s KLL dajali v obliki intravenske infuzije v odmerku 375 mg/m2 telesne površine v prvem ciklu zdravljenja, odmerek pa se je v naslednjih 5 ciklih zdravljenja povečal na 500 mg/m2 telesne površine (v kombinaciji s fludarabinom in ciklofosfamidom).
The efficacy and safety of rituximab in alleviating the symptoms and signs of rheumatoid arthritis in patients with an inadequate response to TNF-inhibitors was demonstrated in a pivotal randomised, controlled, double-blind, multicentre trial (Trial 1). 
ki niso zadostno odgovorili na zdravljenje z zaviralci TNF, sta bili dokazani v ključnem randomiziranem, kontroliranem, dvojno slepem, multicentričnem preskušanju (preskušanje 1).
Ear and labyrinth tinnitus, ear pain hearing loss5 
vključno z motnjami labirinta tinitus, bolečine v ušesu izguba sluha5
Pneumocystis jirovecii pneumonia (PCP) prophylaxis is recommended for patients with GPA/MPA or PV during and following rituximab treatment, as appropriate according to local clinical practice guidelines. 
Pri bolnikih z granulomatozo s poliangiitisom, mikroskopskim poliangiitisom ali navadnim pemfigusom je med zdravljenjem z zdravilom Truxima in po njem priporočljiva profilaksa proti pljučnici, ki jo povzroča Pneumocystis jirovecii, kot je ustrezno glede na lokalne smernice klinične prakse.
How to store Truxima 
Shranjevanje zdravila Truxima
Injury, poisoning and procedural complications 
Poškodbe in zastrupitve in zapleti po posegih z infuzijo povezane reakcije2
cell return, with counts > 10 cells/μL by month 12, increasing to 87% of patients by month 18. 
Pri večini bolnikov (81%) se je število celic B ponovno povečalo na > 10 celic/µl do 12. meseca, do 18.
This syndrome may be associated with some features of tumour lysis syndrome such as hyperuricaemia, hyperkalaemia, hypocalcaemia, hyperphosphataemia, acute renal failure, elevated lactate dehydrogenase (LDH) and may be associated with acute respiratory failure and death. 
hipokalciemijo, hiperfosfatemijo, akutno ledvično odpoved, zvišano laktat-dehidrogenazo (LDH), ter ga lahko spremlja akutna odpoved dihal in smrt.
How much and how often you will receive your treatment a) 
Koliko zdravila boste dobili in kako pogosto a) Če se zdravite zaradi ne-Hodgkinovega limfoma
Truxima in combination with chemotherapy destroys these cells which are gradually removed from the body by biological processes. 
Zdravilo Truxima v kombinaciji s kemoterapijo uniči te celice.
Truxima is used for the treatment of rheumatoid arthritis. 
Zdravilo Truxima uporabljamo za zdravljenje revmatoidnega artritisa, ki je bolezen sklepov.
Truxima has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. 
Zdravilo Truxima v kombinaciji z metotreksatom zmanjša hitrost napredovanja okvar sklepov, ki jih spremljamo z rentgenskim slikanjem, in izboljša funkcijsko zmogljivost.
Sodium chloride Tri-sodium citrate dihydrate Polysorbate 80 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi natrijev klorid trinatrijev citrat dihidrat polisorbat 80 voda za injekcije
Measure blood neutrophils prior to each course of rituximab, and regularly up to 6-months after cessation of treatment, and upon signs or symptoms of infection (see section 4.8). 
6 mesecev po končanem zdravljenju ter pri znakih ali simptomih okužbe (glejte poglavje 4.8).
Adverse drug reaction rituximab + low-dose prednisone (n = 38) 
Rituksimab + majhen odmerek rednizona (n = 38)
Clinical experience in non-Hodgkin's lymphoma and in chronic lymphocytic leukaemia 
Klinične izkušnje pri ne-Hodgkinovem limfomu in kronični limfocitni levkemiji Folikularni limfom
Truxima is provided in sterile, preservative-free, non-pyrogenic, single use vials. 
Rituksimab je bistra brezbarvna tekočina v sterilnih vialah za enkratno uporabo, apirogena in brez konzervansov.
A total of 197 patients aged 15 years or older with severe active granulomatosis with polyangiitis (75%) and microscopic polyangiitis (24%) were enrolled and treated in an active-comparator, randomised, double-blind, multicentre, non-inferiority trial. 
V randomiziranem, dvojno slepem, s placebom kontroliranem multicentričnem preskušanju neinferiornosti z aktivnim primerjalnim zdravilom so vključili in v njej zdravili skupno 197 bolnikov, starih 15 let ali več s hudo, aktivno granulomatozo s poliangiitisom (75 %) in mikroskopskim poliangiitisom (24%).
Cases of posterior reversible encephalopathy syndrome (PRES) / reversible posterior leukoencephalopathy syndrome (RPLS) have been reported. 
Poročali so o primerih sindroma posteriorne reverzibilne encefalopatije (posterior reversible encephalopathy syndrome - PRES)/oziroma sindroma reverzibilne posteriorne levkoencefalopatije (reversible posterior leukoencephalopathy syndrome - RPLS).
Gastrointestinal disorders dyspepsia, diarrhoea, gastro-oesophageal reflux, mouth ulceration, upper abdominal pain 
Bolezni prebavil dispepsija, diareja, gastroezofagealni refluks, razjede v ustih,
You should also tell them about your Truxima treatment. 
Povejte, da se zdravite z zdravilom Truxima.
Truxima 500 mg concentrate for solution for infusion 
Truxima 500 mg koncentrat za raztopino za infundiranje
The recommended dose of Truxima used as a maintenance treatment for patients with relapsed/refractory follicular lymphoma who have responded to induction treatment is: 375 mg/m2 body surface area once every 3 months (starting 3 months after the last dose of induction therapy) until disease progression or for a maximum period of two years (8 infusions in total). 
• Ponovitev folikularnih limfomov ali neodzivna bolezen Priporočeni odmerek zdravila Truxima za vzdrževalno zdravljenje bolnikov s ponovitvijo folikularnih limfomov ali neodzivno boleznijo, ki so se odzvali na indukcijsko zdravljenje, je: 375 mg/m2 telesne površine enkrat na 3 mesece (z začetkom 3 mesece po zadnjem odmerku indukcijskega zdravljenja) do napredovanja bolezni ali največ dve leti (skupaj 8 infuzij).
The majority of patients (81%) showed signs of B 
Pri večini bolnikov (81 %) se je število celic B ponovno povečalo na > 10 celic/µl do 12.
Risk reduction1) 
R-CHOP Vrednost p Zmanjšanje tveganja1)
The chemotherapy should be given after Truxima infusion. 
Kemoterapijo dajemo po infuziji zdravila Truxima.
The recommended dosage of Truxima for the treatment of pemphigus vulgaris is 1000 mg administered as an IV infusion followed two weeks later by a second 1000 mg IV infusion in combination with a tapering course of glucocorticoids. 
Priporočeni odmerek zdravila Truxima za zdravljenje navadnega pemfigusa je 1.000 mg v intravenski infuziji, ki ji čez dva tedna sledi druga intravenska infuzija 1.000 mg; uporablja se v kombinaciji z glukokortikoidi, katerih odmerke postopoma zmanjšujemo.
• If you are having Truxima alone Truxima will be given to you once a week for 4 weeks. 
ga boste prejeli enkrat na teden 4 tedne.
In pooled data from three trials, 39 patients with relapsed or chemoresistant, bulky disease (single lesion ≥ 10 cm in diameter), low grade or follicular B cell NHL received 375 mg/m2 of rituximab as intravenous infusion weekly for four doses. 
Združeni podatki treh preskušanj navajajo, da je 39 bolnikov, pri katerih se je nizko maligni ali folikularni B-celični ne-Hodgkinov limfom ponovil ali pa so bili bolniki neodzivni na kemoterapijo in so imeli obsežno bolezen (ena lezija ≥ 10 cm v premeru), prejelo 4 odmerke po 375 mg/m2 rituksimaba v obliki intravenske infuzije enkrat na teden.
For CLL patients whose lymphocyte counts are > 25 x 109/L it is recommended to administer prednisone/prednisolone 100 mg intravenous shortly before infusion with Truxima to decrease the rate and severity of acute infusion reactions and/or cytokine release syndrome. 
povezanih z infuzijo, in/ali sindroma sproščanja citokinov priporočljivo intravensko dati 100 mg prednizona/prednizolona malo pred infuzijo zdravila Truxima.
They were characterised by pulmonary events and in some cases included rapid tumour lysis and features of tumour lysis syndrome in addition to fever, chills, rigors, hypotension, urticaria, angioedema and other symptoms (see section 4.8). 
Značilni zanje so bili pljučni dogodki in v nekaterih primerih hiter razpad tumorja z značilnostmi sindroma razpada tumorja, poleg zvišane telesne temperature, mrzlice, drgetanja,
• a complex of symptoms occurring within a few weeks of an infusion of Truxima including allergic like reactions such as rash, itching, joint pain, swollen lymph glands and fever 
Zelo redki neželeni učinki (pojavijo se lahko pri 1 od 10.000 bolnikov): skupek simptomov, ki se pojavi v nekaj tednih po prejemu infuzije zdravila Truxima, in vključuje alergijske reakcije, kot so kožni izpuščaji, srbenje, bolečine v sklepih, otekle bezgavke in zvišano telesno temperaturo,
For retreatment with Truxima monotherapy for patients who have responded to previous treatment with Truxima monotherapy for relapsed/refractory follicular lymphoma, the recommended dose is: 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for 4 weeks (see section 5.1). 
Priporočeni odmerek zdravila Truxima za ponovno samostojno zdravljenje bolnikov s folikularnim limfomom, ki so se odzvali na prejšnje samostojno zdravljenje z zdravilom Truxima po tem, ko se na predhodno zdravljenje niso odzvali ali se je pri njih bolezen ponovila, je: 375 mg/m2 telesne površine v obliki intravenske infuzije enkrat na teden 4 tedne (glejte poglavje 5.1).